Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex-Membranoembranoproliferative Glomerulonephritis: PRISM-C3, a Multicountry Phase 4 Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO17-SA; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The findings of this real-world study will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad population of patients with C3G or pIC-MPGN and may help to optimize evidence-based clinical practice. Assessing disease-specific biomarkers is a novel and valuable addition to evaluating the real-world effectiveness of pegcetacoplan."
Clinical • P4 data • Real-world • Real-world effectiveness • Real-world evidence • Chronic Kidney Disease • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease
|
|
David Kavanagh; Matthew C. Pickering; Terence Cook; Marina Vivarelli; Moglie Le Quintrec; Veronique Fremeaux Bacchi; Ginny Taliadouros; Elena Surova; Nicholas J. Webb; Fadi Fakhouri
|